CD22: Difference between revisions

Revision as of 22:13, 9 May 2023

Summary

xxxx

Normal expression and function

xxxxx

Diagnostic role

xxxxx

Other relevant information:

xxxxx

SUMMARY TABLES

Note The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click here. For further information about a particular disease state click <I> adjacent to the condition name

Expression in primitive cell types
AML	CMML	B ALL	Burkitt	T ALL	ETP ALL <I>	MPAL <I>	Hgns <I>
? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%

Notes: xxxxx

Expression in mature B cell neoplasms
CLL	MCL	FL	MZL	HCL	DLBCL	LPL	PCL
? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%

Notes: xxxxx

Expression in mature T cell neoplasms*
ATLL	CTCL/Sezary	T-PLL	T-LGL	NK-LGL
? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%	? <5% 5-20% 20-40% 40-80% 80-100%

Notes: xxxxx

@@ Line 1: / Line 1: @@
-CD22 expression is largely restricted to b cell lineage and expression is acquired at an early differentiation stage.
-*expression varies during mature b-cell development however the major value of CD22 lies in the identification of all based on high lineage-specificity and very early acquisition allowing the identification of pro-b all.
-normal expression and function
+<div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em;  margin-right: 5px;">
-CD22 is a membrane receptor that binds sialic acid containing glycans and expression is mostly restricted to b cells where it is believed to be a negative regulator of activation. expression is developmentally related - first appearing in cytoplasm then on the surface in pre-b cells CD22 is fully expressed by mature b cells but lost on plasma cell differentiation. basophils express CD22.
-other relevant information
-as a result of its restricted expression CD22 has emerged as a therapeutic target in acute lymphoblastic leukemia all and other b cell disorders.
-diagnostic role
+:<span style="color:navy">'''Summary'''</span>
-*its early cytoplasmic expression gives CD22 particular value in the detection of pro b-all diagnosis requires expression of two of the following three markers CD22 membrane or cytoplasm ; CD19 or CD79a. CD22 may not be uniformly expressed across the population with expression being seen on 60-90 of cells.
-*in mature b cell neoplasms CD22 has relatively low expression in cll mcl and fcl but has markedly increased expression in hcl and related disorders.
+:xxxx
+</div>
+<span style="color:navy">'''Normal expression and function'''</span>
+xxxxx
+<span style="color:navy">'''Diagnostic role'''</span>
+*xxxxx
- ----  summary tables
-. expression by acute leukaemias and by haematogones file freqepng  pro-b all  link flow cytometry key file hiepng  early pre-b all  link flow cytometry key file hiepng  pre-b all  link flow cytometry key file hiepng  early b all  link flow cytometry key file rareepng  pro-t all  link flow cytometry key file rareepng  mature-t all  link flow cytometry key file rareepng  aml  link flow cytometry key file hiepng  haemato-gones  link flow cytometry key  *basophils are recognised to express CD22
-. expression by b-lymphoproliferative disorders file hiepng frame  cll * link flow cytometry key file hiepng  pll**  link flow cytometry key file hiepng  mcl  link flow cytometry key file hiepng  fl  * link flow cytometry key file hiepng  hcl**  link flow cytometry key file hiepng  hclv  link flow cytometry key file hiepng  mzl  link flow cytometry key file hiepng  lpl  link flow cytometry key file possepng  pcs  link flow cytometry key  *  typically weak  **  typically strong ----
+<span style="color:navy">'''Other relevant information:'''</span>
+xxxxx
+----
+<span style="color:navy">'''''SUMMARY TABLES'''''</span>
+<span style="font-size:90%">'''Note''' The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click [[Key to marker expression table|here]]. For further information about a particular disease state click <<span style="color:blue>'''I'''</span>> adjacent to the condition name</span>
+{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
+|-
+!colspan="8"|<span style="font-size:100%">'''Expression in primitive cell types'''</font>
+|-
+! AML !! CMML !! B ALL !! Burkitt || T ALL !! ETP ALL <'''[[ETP ALL|I]]'''> !! MPAL <'''[[MPAL|I]]'''> || Hgns <'''[[Hgns|I]]'''>
+|-
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|-
+|}
+<span style="font-size:90%">'''Notes:''' xxxxx </span>
+{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
+|-
+!colspan="8"|'''Expression in mature B cell neoplasms'''
+|-
+! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL
+|-
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|-
+|}
+<span style="font-size:90%">'''Notes:''' xxxxx </span>
+{| class=wikitable style="text-align: center; font-size:80%; width: 62.4%; height 40px;"
+|-
+!colspan="7"|'''Expression in mature T cell neoplasms*'''
+|-
+! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL
+|-
+|style="width: 14.25%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 14.25%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 14.25%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 14.25%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|style="width: 14.25%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
+|-
+|}
+<span style="font-size:90%">'''Notes:''' xxxxx </span>
+----

CD22: Difference between revisions

From haematologyetc.co.uk

Revision as of 22:13, 9 May 2023